EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Polo‐Like Kinase 1 Expression in Colorectal Cancer: Association With RAS Mutations

Yasushi Tanaka iD, Eiji Oki iD, Ryota Nakanishi, Tetsuro Kawazoe, Kensuke Kudo, Yoko Zaitsu, Yuichi Hisamatsu iD, Koji Ando, Yoshinao Oda iD, Tomoharu Yoshizumi

Cancer Science · 2025

DOI: 10.1111/cas.70088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Yasushi Tanaka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Protein Serine-Threonine Kinases, Proto-Oncogene Proteins, Mutation. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polo‐like kinase 1 (PLK1) controls mitotic spindle formation and cytokinesis. However, its role as a predictive biomarker for treatment outcomes in colorectal cancer (CRC) remains underexplored, particularly in the context of RAS mutations. We retrospectively analyzed the relationships among PLK1 expression, clinicopathological factors, and survival in 225 patients who underwent CRC surgery. We also analyzed the relationship between PLK1 expression and survival after adjuvant chemotherapy and how RAS mutation influenced the prognosis. We found that PLK1 expression was significantly correlated with histopathology ( p < 0.0001) and perineural invasion ( p = 0.005). The high PLK1 expression group tended to have a worse prognosis in terms of relapse‐free survival than the low expression group for all patients ( p = 0.060) and patients with stage III disease ( p = 0.055). In patients who received adjuvant chemotherapy for stage III CRC, high PLK1 expression was the only poor prognostic factor for relapse‐free survival ( p = 0.01), and those with mutated RAS had a significantly poorer prognosis than those with wild‐type RAS ( p = 0.027). In patients with CRC, high PLK1 expression was associated with poor survival after adjuvant chemotherapy, and there was potential involvement of the RAS mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProtein Serine-Threonine KinasesProto-Oncogene ProteinsMutationCell Cycle Proteinsras ProteinsHumansPolo-Like Kinase 1MaleFemaleMiddle AgedAgedPrognosisRetrospective StudiesAdultAged, 80 and overBiomarkers, TumorChemotherapy, AdjuvantDisease-Free SurvivalNeoplasm Staging

Stichwörter der Autor:innen

RASadjuvant chemotherapycolorectal cancerpolo‐like kinase 1prognosis

Substanzen

Polo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsCell Cycle ProteinsBiomarkers, Tumorras Proteins

Autor:innen und Institutionen

  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

ORCID-Profile: Yasushi Tanaka, Eiji Oki, Yuichi Hisamatsu, Yoshinao Oda

Zitieren

APA

Tanaka, Y., Oki, E., Nakanishi, R., Kawazoe, T., Kudo, K., Zaitsu, Y., Hisamatsu, Y., Ando, K., Oda, Y., & Yoshizumi, T. (2025). Polo‐Like Kinase 1 Expression in Colorectal Cancer: Association With RAS Mutations. Cancer Science. https://doi.org/10.1111/cas.70088

Vancouver

Tanaka Y, Oki E, Nakanishi R, Kawazoe T, Kudo K, Zaitsu Y, et al. Polo‐Like Kinase 1 Expression in Colorectal Cancer: Association With RAS Mutations. Cancer Science. 2025. doi:10.1111/cas.70088

BibTeX
@article{Tanaka2025,
  author = {Tanaka, Yasushi and Oki, Eiji and Nakanishi, Ryota and Kawazoe, Tetsuro and Kudo, Kensuke and Zaitsu, Yoko and Hisamatsu, Yuichi and Ando, Koji and Oda, Yoshinao and Yoshizumi, Tomoharu},
  title = {Polo‐Like Kinase 1 Expression in Colorectal Cancer: Association With RAS Mutations},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70088}
}
Kostenlos starten →